Literature DB >> 28154173

Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6.

Miki Furukawa1, Hiroshi Ohkawara2, Kazuei Ogawa1, Kazuhiko Ikeda1,3, Koki Ueda1, Akiko Shichishima-Nakamura1, Emi Ito4, Jun-Ichi Imai4, Yuka Yanagisawa4, Reiko Honma5, Shinya Watanabe4, Satoshi Waguri4, Takayuki Ikezoe1, Yasuchika Takeishi6.   

Abstract

The pathogenesis of multiple myeloma (MM) has not yet been fully elucidated. Our microarray analysis and immunohistochemistry revealed significant up-regulation of growth arrest-specific gene 6 (Gas6), a vitamin K-dependent protein with a structural homology with protein S, in bone marrow (BM) cells of MM patients. ELISA showed that the serum levels of soluble Gas6 were significantly increased in the MM patients when compared with healthy controls. Gas6 was overexpressed in the human CD138-positive MM cell line RPMI-8226. Exogenous Gas6 suppressed apoptosis induced by serum deprivation and enhanced cell proliferation of the MM cells. The conditional medium from the human BM stromal cell line HS-5 induced cell proliferation and anti-apoptosis of the MM cells with extracellular signal-regulated kinase, Akt, and nuclear factor-κB phosphorylation, which were reversed by the neutralizing antibody to Gas6 or IL-6. The TAM family receptor Mer, which has been identified as a Gas6 receptor, was overexpressed in BM cells of MM patients. The knockdown of Mer by siRNA inhibited cell proliferation, anti-apoptosis, and up-regulation of intercellular cell adhesion molecule-1 (ICAM-1) in MM cells stimulated by an HS-5 cell-conditioned medium. Furthermore, the Gas6-neutralizing antibody reduced the up-regulation of IL-6 and ICAM-1 induced by a HS-5 cell-conditioned medium in MM cells. The present study provides new evidence that autocrine and paracrine stimulation of Gas6 in concert with IL-6 contributes to the pathogenesis of MM, suggesting that Gas6-Mer-related signaling pathways may be a promising novel target for treating MM.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  apoptosis; bone marrow; cell proliferation; interleukin 6 (IL-6); multiple myeloma; stromal cell

Mesh:

Substances:

Year:  2017        PMID: 28154173      PMCID: PMC5354500          DOI: 10.1074/jbc.M116.733030

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  Inhibiting IL-6 in human multiple myeloma.

Authors:  B Klein; Z Y Lu; J P Gaillard; J L Harousseau; R Bataille
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

2.  Differential responses of normal human coronary artery endothelial cells against multiple cytokines comparatively assessed by gene expression profiles.

Authors:  Aya Miura; Reiko Honma; Takushi Togashi; Yuka Yanagisawa; Emi Ito; Jun-Ichi Imai; Takao Isogai; Naoki Goshima; Shinya Watanabe; Nobuo Nomura
Journal:  FEBS Lett       Date:  2006-11-27       Impact factor: 4.124

Review 3.  Crosstalk in NF-κB signaling pathways.

Authors:  Andrea Oeckinghaus; Matthew S Hayden; Sankar Ghosh
Journal:  Nat Immunol       Date:  2011-07-19       Impact factor: 25.606

4.  CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.

Authors:  Yu-Tzu Tai; Klaus Podar; Nicholas Mitsiades; Boris Lin; Constantine Mitsiades; Deepak Gupta; Masaharu Akiyama; Laurence Catley; Teru Hideshima; Nikhil C Munshi; Steven P Treon; Kenneth C Anderson
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

5.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.

Authors:  B Dankbar; T Padró; R Leo; B Feldmann; M Kropff; R M Mesters; H Serve; W E Berdel; J Kienast
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

6.  A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma.

Authors:  Markus Hansson; Peter Gimsing; Ashraf Badros; Titti Martinsson Niskanen; Hareth Nahi; Fritz Offner; Morten Salomo; Elisabeth Sonesson; Morten Mau-Sorensen; Yvonne Stenberg; Annika Sundberg; Ingrid Teige; Jan Van Droogenbroeck; Stina Wichert; Maurizio Zangari; Björn Frendeus; Magnus Korsgren; Martine Poelman; Guido Tricot
Journal:  Clin Cancer Res       Date:  2015-02-24       Impact factor: 12.531

7.  Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma.

Authors:  B Arnulf; S Lecourt; J Soulier; B Ternaux; M-Noelle Lacassagne; A Crinquette; J Dessoly; A-K Sciaini; M Benbunan; C Chomienne; J-P Fermand; J-P Marolleau; J Larghero
Journal:  Leukemia       Date:  2006-11-09       Impact factor: 11.528

8.  GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche.

Authors:  Yusuke Shiozawa; Elisabeth A Pedersen; Russell S Taichman
Journal:  Exp Hematol       Date:  2009-11-14       Impact factor: 3.084

9.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors:  Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

Review 10.  Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.

Authors:  Constantine S Mitsiades; Faith E Davies; Jacob P Laubach; Douglas Joshua; Jesus San Miguel; Kenneth C Anderson; Paul G Richardson
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

View more
  13 in total

1.  Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signalling.

Authors:  Nidhi Gupta; Raman Kumar; Tulika Seth; Bhavuk Garg; Alpana Sharma
Journal:  RNA Biol       Date:  2019-09-29       Impact factor: 4.652

2.  A critical role of the Gas6-Mer axis in endothelial dysfunction contributing to TA-TMA associated with GVHD.

Authors:  Miki Furukawa; Xintao Wang; Hiroshi Ohkawara; Masahiko Fukatsu; Lobna Alkebsi; Hiroshi Takahashi; Kayo Harada-Shirado; Akiko Shichishima-Nakamura; Satoshi Kimura; Kazuei Ogawa; Takayuki Ikezoe
Journal:  Blood Adv       Date:  2019-07-23

3.  Remission of light chain proximal tubulopathy in IgG λ-type multiple myeloma by lenalidomide and dexamethasone therapy.

Authors:  Shinya Kawamoto; Yuji Hidaka; Yu Kaneko; Hideo Misawa; Katsuhiro Nagahori; Atsunori Yoshino; Takamitsu Okamura; Shinichi Ban; Yoshihiko Ueda; Tetsuro Takeda
Journal:  CEN Case Rep       Date:  2019-02-05

4.  A 3D-Bioprinted Multiple Myeloma Model.

Authors:  Di Wu; Zongyi Wang; Jun Li; Yan Song; Manuel Everardo Mondragon Perez; Zixuan Wang; Xia Cao; Changliang Cao; Sushila Maharjan; Kenneth C Anderson; Dharminder Chauhan; Yu Shrike Zhang
Journal:  Adv Healthc Mater       Date:  2021-09-23       Impact factor: 11.092

5.  A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance.

Authors:  Christina Mark; Jay Warrick; Natalie S Callander; Peiman Hematti; Shigeki Miyamoto
Journal:  Mol Cancer Res       Date:  2022-09-02       Impact factor: 6.333

6.  IL-6 blockade reverses bone marrow failure induced by human acute myeloid leukemia.

Authors:  Tian Yi Zhang; Ritika Dutta; Brooks Benard; Feifei Zhao; Raymond Yin; Ravindra Majeti
Journal:  Sci Transl Med       Date:  2020-04-08       Impact factor: 17.956

7.  Tumour-Secreted Protein S (ProS1) Activates a Tyro3-Erk Signalling Axis and Protects Cancer Cells from Apoptosis.

Authors:  Nour Al Kafri; Sassan Hafizi
Journal:  Cancers (Basel)       Date:  2019-11-22       Impact factor: 6.639

8.  Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multiple myeloma via ERK/STAT3 axis.

Authors:  Zhaoyuan Zhang; Weili Wang; Dan Ma; Jie Xiong; Xingyi Kuang; Siyu Zhang; Qin Fang; Jishi Wang
Journal:  Aging (Albany NY)       Date:  2020-04-16       Impact factor: 5.682

9.  The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.

Authors:  Pasupathi Sundaramoorthy; Cristina Gasparetto; Yubin Kang
Journal:  Cancer Med       Date:  2018-05-15       Impact factor: 4.452

10.  A worm gel-based 3D model to elucidate the paracrine interaction between multiple myeloma and mesenchymal stem cells.

Authors:  Renza Spelat; Federico Ferro; Paolo Contessotto; Nicholas J Warren; Grazia Marsico; Steven P Armes; Abhay Pandit
Journal:  Mater Today Bio       Date:  2020-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.